Association of GSK3B with Alzheimer disease and frontotemporal dementia

Barbara A.J. Schaffer, Lars Bertram, Bruce L. Miller, Kristina Mullin, Sandra Weintraub, Nancy Johnson, Eileen H. Bigio, Marsel Mesulam, Martina Wiedau-Pazos, George R. Jackson, Jeffrey L. Cummings, Rita M. Cantor, Allan I. Levey, Rudolph E. Tanzi, Daniel H. Geschwind

Research output: Contribution to journalArticle

71 Scopus citations

Abstract

Background: Deposits of abnormally hyperphosphorylated tau are a hallmark of several dementias, including Alzheimer disease (AD), and about 10% of familial frontotemporal dementia (FTD) cases are caused by mutations in the tau gene. As a known tau kinase, GSK3B is a promising candidate gene in the remaining cases of FTD and in AD, for which tau mutations have not been found. Objective: To examine the promoter of GSK3B and all 12 exons, including the surrounding intronic sequence, in patients with FTD, patients with AD, and aged healthy subjects to identify single-nucleotide polymorphisms associated with disease. Design, Setting, and Participants: Single-nucleotide polymorphism frequency was examined in a case-control cohort of 48 patients with probable AD, 102 patients with FTD, 38 patients with primary progressive aphasia, and 85 aged healthy subjects. Results were followed up in 2 independent AD family samples consisting of 437 multiplex families with AD (National Institute of Mental Health Genetics Initiative AD Study) or 150 sibships discordant for AD (Consortium on Alzheimer's Genetics Study). Results: Several rare sequence variants in GSK3B were identified in the case-control study. An intronic polymorphism (IVS2-68G>A) occurred at more than twice the frequency among patients with FTD (10.8%) and patients with AD (14.6%) than in aged healthy subjects (4.1%). The polymorphism showed association with disease in both follow-up samples independently, although only the Consortium on Alzheimer's Genetics sample showed the same direction of association as the case-control sample. Conclusions: To our knowledge, this is the first evidence that a gene known to be involved in tau phosphorylation, GSK3B, is associated with risk for primary neurodegenerative dementias. This supports previous work in animal models suggesting that such genes are therapeutic targets.

Original languageEnglish (US)
Pages (from-to)1368-1374
Number of pages7
JournalArchives of Neurology
Volume65
Issue number10
DOIs
StatePublished - Oct 2008

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Association of GSK3B with Alzheimer disease and frontotemporal dementia'. Together they form a unique fingerprint.

  • Cite this

    Schaffer, B. A. J., Bertram, L., Miller, B. L., Mullin, K., Weintraub, S., Johnson, N., Bigio, E. H., Mesulam, M., Wiedau-Pazos, M., Jackson, G. R., Cummings, J. L., Cantor, R. M., Levey, A. I., Tanzi, R. E., & Geschwind, D. H. (2008). Association of GSK3B with Alzheimer disease and frontotemporal dementia. Archives of Neurology, 65(10), 1368-1374. https://doi.org/10.1001/archneur.65.10.1368